Examkin

Soru

Zorluk: OrtaImmunologic and Inflammatory Processes

A 52-year-old man presents to the clinic for a follow-up evaluation of seropositive rheumatoid arthritis. Over the past 8 months, he has been treated with optimized doses of methotrexate, but he continues to experience significant morning stiffness and synovitis in his metacarpophalangeal and proximal interphalangeal joints. The physician decides to initiate targeted therapy with infliximab. Prior to starting the medication, an interferon-gamma release assay (IGRA) is performed and returns positive. A subsequent chest radiograph is clear, and the patient reports no cough, fever, or weight loss. Which of the following immunologic processes is most directly impaired by the planned biologic therapy, prompting the need for this screening?

  1. Macrophage activation and maintenance of caseating granulomasCevap
  2. B
    Proliferation and differentiation of CD4+ T helper 1 cells
  3. C
    Neutrophil recruitment and formation of microabscesses
  4. D
    Antibody-mediated opsonization of intracellular pathogens
  5. E
    Major histocompatibility complex class II antigen presentation

Cevap

Macrophage activation and maintenance of caseating granulomas
The correct answer identifies the fundamental role of TNF-alpha in the immune response to Mycobacterium tuberculosis. Alveolar macrophages and CD4+ Th1 cells interact closely to contain the pathogen. Th1 cells secrete interferon-gamma (IFN-gamma), which activates macrophages. These activated macrophages subsequently secrete TNF-alpha, a critical cytokine that drives the recruitment of additional immune cells and promotes the structural integrity of caseating granulomas. These granulomas wall off the mycobacteria, maintaining them in a dormant state. Biologic agents like infliximab, adalimumab, and etanercept neutralize TNF-alpha, which directly causes the dissolution of these granulomas. This leads to the rapid reactivation and dissemination of latent tuberculosis, which is why screening with an interferon-gamma release assay (IGRA) or tuberculin skin test is mandatory prior to initiating anti-TNF therapy.

Adım Adım Çözüm

1
Identify the mechanism of action of the planned medication.
Infliximab is a monoclonal antibody that targets and neutralizes tumor necrosis factor-alpha (TNF-alpha).
Understanding the pharmacodynamics of the drug is essential to predict its immunologic side effects.
2
Interpret the pre-treatment screening test results.
A positive IGRA with a normal chest radiograph and no symptoms indicates latent tuberculosis infection (LTBI).
Differentiating latent infection from active disease dictates the need for prophylactic management versus active treatment before starting immunosuppression.
3
Correlate the drug's mechanism with the pathophysiology of latent tuberculosis.
TNF-alpha is critical for the maintenance of caseating granulomas that keep Mycobacterium tuberculosis in a dormant state. Inhibiting TNF-alpha leads to granuloma dissolution and tuberculosis reactivation.
Connecting the immunologic pathway to the infectious complication explains why screening is a mandatory guideline.

Anahtar Kavram

Tumor necrosis factor-alpha (TNF-alpha) is crucial for macrophage activation and the maintenance of granulomas; its inhibition by biologic agents like infliximab significantly increases the risk of latent tuberculosis reactivation.
Bu soruyu puanla

Konular

Immunologic and Inflammatory Processes

Bu konudan daha fazla soru